LEXXW - Lexaria Completes Successful Antiviral Drug Molecular Characterization Study with Canada's National Research Council
(TheNewswire)
VIRAL-MC21-1 Demonstrates Stabilityof DehydraTECH™-Enabled Antiviral Drugs
Kelowna, British Columbia - TheNewswire – July 15, 2021 – Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the“Company” or “Lexaria”), a global innovator in drug deliveryplatforms is pleased to announce results from its antiviral drugmolecular characterization study VIRAL-MC21-1 recently completed byCanada’s premier federally funded research organization, theNational Research Council (“NRC”).
The NRC has successfully confirmed Lexaria’s studyobjectives, demonstrating DehydraTECH™ processing and formulationtechnology does not create a covalently bonded new molecular entity(“NME”) and that each drug tested remained stable and did notundergo change in chemical structure. The five drugs studied wereremdesivir, ebastine, bepridil, rupintrivir and colchicine, which haveantiviral effects through a variety of different modes ofaction.
These findings are strongly supportive of acceleratedregulatory filings such as the 505(b)(2) pathway permitted by the Foodand Drug Administration (“FDA”) and other internationalregulators, for more rapid market authorizations of prospectiveDehydraTECH-enabled, repurposed antiviral drugs. By comparison, NMEs are generally subjected to more involvedregulatory examination and approval processes than non-NMEs.
The work carried out by NRC consisted primarily ofnuclear magnetic resonance (“NMR”) and Liquid Chromatography-High Resolution Mass Spectrometry(“LC-HRMS”) evaluations. NMR spectroscopyis an analytical chemistry method that can determine purity andmolecular structures. LC-HRMS uses mass spectrometers and can be usedto determine elemental compositions and distinguish between differentmolecules.
As Lexaria’s validating datasets continue to grow, the Company willpursue strategic collaboration opportunities with establishedpharmaceutical industry partners to incorporate DehydraTECH technologywith antiviral drugs including and/or similar to those that arecurrently being investigated.
DRUG USES:
REMDESIVIR is a well-known nucleotide reversetranscriptase inhibitor, available under the trade name Veklury® fromGilead Sciences Inc., that interferes with the SARS-CoV-2 viralreplication life cycle and has received emergency use authorization inmany regions of the world for treatment ofCOVID-19. It is also used totreat hepatitis, Ebola disease and Marburg virus infections.
EBASTINE is an antihistamine drug that has potenteffects in inhibiting the SARS-CoV-2 main protease (Mpro, also calledthe 3CL protease) blocking viral entry into humancells , together with effects toreduce COVID-19 inflammatoryreactions . It is also usedto treat allergic rhinitis, hives, idiopathic urticaria, and relieffrom mosquito bites and atopic dermatitis.
BEPRIDIL is used primarily to treat angina pectoris due to coronaryheart disease and is indicated to treat chronic stable angina; isbeing investigated to treat atrial fibrillation ; and, in at least one cellularstudy utilizing Vero E6 cells, was shown to inhibit cytopathogeniceffect induces by SARS-CoV-2.
RUPINTRIVIR was originally developed for treatment of rhinoviruses (common colds) and isalso being investigated for treatment of picornaviruses, norovirus, and coronaviruses such as SARS-CoV-2.
COLCHICINE is an approved therapeutic withanti-inflammatory effects that is principally used to treat gout andconditions like cardiacinflammation (i.e., pericarditis),but also has potent effects in mitigating the cytokinestorm associated withSARS-CoV-2/COVID-19. Colchicine is also sometimes recommended andused to treat emergent pericarditis in children in cases where thisform of cardiac inflammation develops following administration of mRNACOVID-19 vaccines. It is also used to treat atrialfibrillation and Periodic Fever Syndromes.
Chris Bunka, CEO, is responsible for the accuracy ofthis press release. The Company is not making any express or impliedclaims that its products have the ability to eliminate, cure orcontain the COVID-19 pandemic (or SARS-CoV-2 or novel Coronavirus) orany other virally induced diseases at this time.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. Since 2016, DehydraTECH has repeatedly demonstrated theability to increase bio-absorption withcannabinoids and nicotine by up to 5-10x, reducetime of onset from 1 - 2 hours to minutes, and mask unwanted tastes;and is planned to be further evaluated for orally administeredbioactive molecules, including anti-viral drugs, vitamins,non-steroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria haslicensed DehydraTECH to multiple companies including a world-leadingtobacco producer for the development of smokeless, oral-based nicotineproducts and for use in industries that produce cannabinoid beverages,edibles, and oral products. Lexaria operates a licensed in-houseresearch laboratory and holds a robust intellectual property portfoliowith 20 patents granted and over 50 patents pending worldwide. Formore information, please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties,and there can be no assurance that the Company will actually achievethe plans, intentions, or expectations disclosed in theseforward-looking statements. As such, you should not place unduereliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the US Securities and Exchange Commission on EDGAR. Thereis no assurance that any of Lexaria’s postulated uses, benefits, oradvantages for the patented and patent-pending technology will in factbe realized in any manner or in any part. No statement herein has beenevaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat,cure or prevent any disease. Any forward-looking statements containedin this release speak only as of the datehereof, and the Company expressly disclaims any obligation to updateany forward-looking statements contained herein, whether as a resultof any new information, future events, changed circumstances orotherwise, except as otherwise required by law.
Copyright (c) 2021 TheNewswire - All rights reserved.